Sun, May 26, 2013, 4:07 AM EDT - U.S. Markets closed
Pfizer had to take it s AML product 'Mylotarg from the market. FDA: Serious safety concerns, no long-term efficacy, but a trend towards more deaths. Therefore quite different to Ceplene. Should have a positive impact for Ceplene's FDA submission: No virtual AML alternative. BTW: This Pfizer drug had an accelerated FDA approval.Hopefully our EPCT mgmt clowns will grasp this time the chance, and do not screw it up.
pathfinder, we talk about diamonds in the hands of pocket thieves. Talley is killing the share price and self-service Soprano rewards him for that with a higher salary. You can call their game stockholder fraud.
Don't say that you were fooled.Now starts a journey. It will not be strait, but do not hesitate about the main direction.You now have the time to leave the bitterness behind. Grab it - or leave.Am I clear enough?
> Hopefully our EPCT mgmt clowns will grasp this time the chance, and do not screw it up. <In fact, that's the problem. Talley & Savage board represent a unique mixture of impudent greediness and technical incompetence Looks like the BP disaster
gunvalst,We have read your anger here on Yahoo for a year now. This is the only CO you seems to follow / write about.Do you recommened your readers to buy or sell Epicept in todays trading?
Nice to hear some serious thought, Pathfinder.Here some more for the one's who pay interest:http://diabetes.diabetesjournals.org/content/57/6/1556.full.pdf+html
Sorry, I brought you the old link, this is the new one from June 2010:http://www.ncbi.nlm.nih.gov/pubmed/20332344